The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

SNAP-8

SNAP-8 · Acetyl Octapeptide-3 · Acetyl Glutamyl Heptapeptide-1

C
Animal replicated
RouteTopicalGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Acetyl Octapeptide-3 / Acetyl Glutamyl Heptapeptide-1 — INCI: Acetyl Octapeptide-3 — Cosmetic Peptide, SNARE Modulator, Acetyl Octapeptide.
Why people use it
Concentration · Dynamic vs Static Wrinkles · The Cosmeceutical Anti-Wrinkle Peptide Stack · Application Protocol
If you only read one thing

SNAP-8 is built on a pharmacological concept of genuine elegance: if the SNARE complex is how NMJs signal muscle contraction, and SNAP-25 N-terminal sequence is how SNAP-25 integrates into that complex, then a competitive peptide mimic should reduce the efficiency of complex assembly and reduce muscle contraction. The in vitro data supports this concept. The challenge is delivery: SNAP-8 is a 1075 Da hydrophilic peptide, and passive penetration through the stratum corneum is severely limited for molecules above ~500 Da. Less than 0.2% of topically applied closely-related Argireline penetrates the stratum corneum (2015 study). The neuromuscular junction sits in the deeper dermis, well below where passive topical SNAP-8 can reach in meaningful quantities. The evidence that SNAP-8 produces clinically meaningful wrinkle reduction in a topical formulation: possible but not established by independent large controlled trials. The evidence that SNAP-8 works via microneedle delivery (bypassing the penetration barrier): more pharmacologically coherent and supported by a small controlled study. The marketing framing of SNAP-8 as 'Botox in a cream' — while mechanistically inspired — significantly overstates both the evidence base and the pharmacological equivalence.

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
0human trials2human studies1animal3in vitro

SNAP-8 human evidence is small cosmetic/open-label or formulation-confounded data; it is designed for topical or microneedle-style cosmetic delivery and is not supported for injection.

Evidence reality check
Human evidence
2 human studies
2 observational; RCT evidence not present in corpus.
Preclinical base
4 lab signals
1 animal; 3 in-vitro/mechanistic.
Risk posture
No major flags listed
Review route-specific cautions before use.
Indication map
Supported / plausible / speculative / avoid
Plausible
Concentration · Dynamic vs Static Wrinkles · The Cosmeceutical Anti-Wrinkle Peptide Stack · Application Protocol
Derived from the chapter quick-reference use-case line; study support varies by use case.
Properties
✓ Human evidenceNot injectable
Evidence
CAnimal replicated
SNAP-8 vs Argireline — What the Two Extra Amino Acids Add
Argireline (acetyl hexapeptide-3/8): 6 amino acids; mimics SNAP-25 N-terminal; MW ~889 Da. SNAP-8: 8 amino acids; same target; two additional amino acids (alanine, aspartate) at the C-terminal; MW ~1075 Da. The additional amino acids improve: SNARE complex binding geometry (better conformational fit at the assembly interface); peptide stability (more resistance to enzymatic degradation); competitive inhibition efficiency. Manufacturer-sponsored comparative studies suggest SNAP-8 is approximately 30% more active than Argireline in anti-wrinkle assays. This ~30% improvement is real in vitro; its clinical significance at topical concentrations is constrained by the penetration limitation both peptides share.
The Mechanism — SNARE Complex vs Botox (Key Distinction)
BOTULINUM TOXIN: zinc metalloprotease; enzymatically cleaves SNARE proteins (specifically SNAP-25) at the neuromuscular junction; irreversible cleavage means the junction is non-functional until new SNARE proteins are synthesized (effect duration: 3-6 months). SNAP-8: mimics SNAP-25 N-terminal sequence; COMPETITIVE inhibition of SNARE complex assembly; reversible; effect requires continuous presence of the peptide at the NMJ; far weaker potency than BoNT. The mechanism analogy: both work 'in the SNARE complex neighborhood.' The pharmacological reality: competitive inhibition by a topically applied peptide is categorically less potent, less durable, and less targeted than enzymatic cleavage by a precision injectable toxin. 'SNAP-8 is like Botox in a cream' — the analogy is mechanistically grounded; the clinical comparison is not supported.
The Penetration Problem — The Most Important Limitation
SNAP-8 is a large (MW ~1075 Da), hydrophilic peptide. Passive dermal penetration of molecules above ~500 Da is limited by the stratum corneum. Directly relevant data from Argireline (same target, same class, MW ~889 Da): a 2015 study showed that after 24 hours of application, less than 0.2% of applied peptide penetrated the stratum corneum, with 99.7% removed after washing. SNAP-8 is larger than Argireline — its passive penetration is likely no better and may be worse. This means that for a 10% SNAP-8 serum applied topically, essentially all of the peptide sits on or in the upper stratum corneum, where the target (neuromuscular junction) is not located. The NMJ is in the deeper dermis, well below the stratum corneum. This penetration gap is the central pharmacological challenge for the entire neuromimetic cosmeceutical peptide class.
The 63% Claim — Context Required
The widely cited '63% wrinkle depth reduction in 28 days' comes from Lipotec's proprietary clinical evaluation data (17 subjects, twice-daily 10% SNAP-8 application). This data has not been published in a peer-reviewed journal as an independent study — it is manufacturer-generated data from the ingredient supplier. The 63% figure refers to wrinkle depth measured by silicon imprint and 3D imaging methodology in a small, uncontrolled study. Independent large-scale RCTs replicating this figure do not exist. A 2024 review notes reports of up to ~38% wrinkle depth reduction in some studies — a more conservative estimate from the broader evidence base. Neither figure has been replicated in an independent large controlled trial.
Microneedle Delivery — The Most Credible Evidence
The most methodologically rigorous published SNAP-8 study uses dissolving microneedle patches rather than passive topical application: Annals of Dermatology: 24-subject trial, 4 weeks, dissolving microneedle patch containing SNAP-8; significant reduction in periorbital wrinkle depth and improved skin elasticity; no adverse effects. Microneedle delivery bypasses the stratum corneum penetration barrier — the tiny needles dissolve in the dermis, delivering SNAP-8 directly to the deeper skin layers where NMJ-adjacent concentrations can be achieved. This is pharmacologically rational: if the penetration barrier is the problem, bypassing it should improve efficacy. The microneedle evidence is Grade C but mechanistically the most coherent evidence for SNAP-8's intended mechanism.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Check interactions